MTOR Inhibitors at a Glance

Overview

Journal Mol Cell Pharmacol

Specialty Biochemistry

Date 2016 May 3

PMID 27134695

Citations 58

Authors

Yin Zheng

Yu Jiang

Affiliations

Soon will be listed here.

Abstract

Mechanistic target of rapamycin (mTOR) is a conserved threonine and serine protein kinase that was identified more than two decades ago as the target of immunosuppressive drug rapamycin. Since then considerable amount of information has been learned about the function of this kinase. It is now well-established that mTOR plays a pivotal role in governing cell growth and proliferation, hence making mTOR a therapeutic target for disease conditions caused by deregulated cell proliferation, such as cancer. In the past decade, numerous mTOR inhibitors have been developed and many are currently in clinical trials for cancer treatment. This commentary is to provide a brief summary of these mTOR inhibitors.

Citing Articles

Adaptive protein synthesis in genetic models of copper deficiency and childhood neurodegeneration.

Lane A, Scher N, Bhattacharjee S, Zlatic S, Roberts A, Gokhale A bioRxiv. 2024; .

PMID: 39314281 PMC: 11419079. DOI: 10.1101/2024.09.09.612106.

IRF5 mediates adaptive immunity via altered glutamine metabolism, mTORC1 signaling and post-transcriptional regulation following T cell receptor activation.

Brune Z, Lu A, Moss M, Brune L, Huang A, Matta B bioRxiv. 2024; .

PMID: 39253451 PMC: 11382993. DOI: 10.1101/2024.08.26.609422.

Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management.

Ellis R, Marquine M, Kaul M, Fields J, Schlachetzki J Nat Rev Neurol. 2023; 19(11):668-687.

PMID: 37816937 PMC: 11052664. DOI: 10.1038/s41582-023-00879-y.

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases.

Semenescu L, Kamel A, Ciubotaru V, Baez-Rodriguez S, Furtos M, Costachi A Curr Issues Mol Biol. 2023; 45(9):7680-7704.

PMID: 37754269 PMC: 10528141. DOI: 10.3390/cimb45090485.

The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?.

Paudel S, Hutzen B, Cripe T Mol Ther Oncolytics. 2023; 30:227-237.

PMID: 37680255 PMC: 10480481. DOI: 10.1016/j.omto.2023.07.008.

References

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

Manning B . Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004; 167(3):399-403. PMC: 2172491. DOI: 10.1083/jcb.200408161. View

Yu P, Laird A, Du X, Wu J, Won K, Yamaguchi K . Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway. Mol Cancer Ther. 2014; 13(5):1078-91. DOI: 10.1158/1535-7163.MCT-13-0709. View

Lawrence J, Lin T, McMahon L, Choi K . Modulation of the protein kinase activity of mTOR. Curr Top Microbiol Immunol. 2003; 279:199-213. DOI: 10.1007/978-3-642-18930-2_12. View

Lempiainen H, Halazonetis T . Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009; 28(20):3067-73. PMC: 2752028. DOI: 10.1038/emboj.2009.281. View

Chresta C, Davies B, Hickson I, Harding T, Cosulich S, Critchlow S . AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2009; 70(1):288-98. DOI: 10.1158/0008-5472.CAN-09-1751. View

Sutherlin D, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I . Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J Med Chem. 2010; 53(3):1086-97. DOI: 10.1021/jm901284w. View

Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S . Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002; 110(2):177-89. DOI: 10.1016/s0092-8674(02)00833-4. View

Bitting R, Armstrong A . Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013; 20(3):R83-99. DOI: 10.1530/ERC-12-0394. View

10.

Kwitkowski V, Prowell T, Ibrahim A, Farrell A, Justice R, Mitchell S . FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist. 2010; 15(4):428-35. PMC: 3227966. DOI: 10.1634/theoncologist.2009-0178. View

11.

Knight S, Adams N, Burgess J, Chaudhari A, Darcy M, Donatelli C . Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett. 2014; 1(1):39-43. PMC: 4007793. DOI: 10.1021/ml900028r. View

12.

Malagu K, Duggan H, Menear K, Hummersone M, Gomez S, Bailey C . The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg Med Chem Lett. 2009; 19(20):5950-3. DOI: 10.1016/j.bmcl.2009.08.038. View

13.

Lou H, Weng X, Pan H, Pan Q, Sun P, Liu L . The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. Biochem Biophys Res Commun. 2014; 450(2):973-8. DOI: 10.1016/j.bbrc.2014.06.081. View

14.

Mohamed A, Krajewski K, Cakar B, Ma C . Targeted therapy for breast cancer. Am J Pathol. 2013; 183(4):1096-1112. DOI: 10.1016/j.ajpath.2013.07.005. View

15.

Fan Q, Knight Z, Goldenberg D, Yu W, Mostov K, Stokoe D . A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006; 9(5):341-9. PMC: 2925230. DOI: 10.1016/j.ccr.2006.03.029. View

16.

Gupta M, Wahner Hendrickson A, Yun S, Han J, Schneider P, Koh B . Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 2011; 119(2):476-87. PMC: 3257013. DOI: 10.1182/blood-2011-04-346601. View

17.

Yuan J, Mehta P, Yin M, Sun S, Zou A, Chen J . PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011; 10(11):2189-99. DOI: 10.1158/1535-7163.MCT-11-0185. View

18.

Huang J, Manning B . A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009; 37(Pt 1):217-22. PMC: 2778026. DOI: 10.1042/BST0370217. View

19.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F . Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008; 17(12):1947-54. DOI: 10.1517/13543780802556485. View

20.

Abraham R, Wiederrecht G . Immunopharmacology of rapamycin. Annu Rev Immunol. 1996; 14:483-510. DOI: 10.1146/annurev.immunol.14.1.483. View